ImmunomeInc Current Financial Leverage
IMNM Stock | USD 17.18 0.20 1.15% |
ImmunomeInc holds a debt-to-equity ratio of 0.006. At this time, ImmunomeInc's Total Debt To Capitalization is very stable compared to the past year. As of the 19th of April 2024, Debt Equity Ratio is likely to grow to 0.02, while Short and Long Term Debt is likely to drop about 335.9 K. ImmunomeInc's financial risk is the risk to ImmunomeInc stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
ImmunomeInc's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. ImmunomeInc's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps ImmunomeInc Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect ImmunomeInc's stakeholders.
For most companies, including ImmunomeInc, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running ImmunomeInc the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 10.2626 | Book Value 2.772 | Operating Margin (3.62) | Return On Assets (0.21) | Return On Equity (1.56) |
ImmunomeInc |
ImmunomeInc Financial Leverage Rating
ImmunomeInc bond ratings play a critical role in determining how much ImmunomeInc have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for ImmunomeInc's borrowing costs.Piotroski F Score | 2 Frail |
Beneish M Score | -3.7 Unlikely Manipulator |
ImmunomeInc Debt to Cash Allocation
As ImmunomeInc follows its natural business cycle, the capital allocation decisions will not magically go away. ImmunomeInc's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 293 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ImmunomeInc has a current ratio of 4.27, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ImmunomeInc until it has trouble settling it off, either with new capital or with free cash flow. So, ImmunomeInc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImmunomeInc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImmunomeInc to invest in growth at high rates of return. When we think about ImmunomeInc's use of debt, we should always consider it together with cash and equity.ImmunomeInc Total Assets Over Time
ImmunomeInc Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the ImmunomeInc's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of ImmunomeInc, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a an ImmunomeInc debt ratio should be compared their industry average or other competing firms.ImmunomeInc Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning ImmunomeInc Use of Financial Leverage
ImmunomeInc financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures ImmunomeInc's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of ImmunomeInc assets, the company is considered highly leveraged. Understanding the composition and structure of overall ImmunomeInc debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to ImmunomeInc's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of ImmunomeInc's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 263.7 K | 474.1 K | |
Net Debt | -18 M | -18.9 M | |
Long Term Debt | 120.6 K | 152.5 K | |
Short and Long Term Debt | 550.9 K | 335.9 K | |
Short Term Debt | 263.7 K | 344.3 K | |
Net Debt To EBITDA | 0.50 | 0.96 | |
Debt To Equity | 0.02 | 0.02 | |
Interest Debt Per Share | 0.03 | 0.03 | |
Debt To Assets | 0.01 | 0.01 | |
Long Term Debt To Capitalization | 0 | 0 | |
Total Debt To Capitalization | 0.02 | 0.02 | |
Debt Equity Ratio | 0.02 | 0.02 | |
Debt Ratio | 0.01 | 0.01 | |
Cash Flow To Debt Ratio | (112.61) | (106.98) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmunomeInc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmunomeInc's short interest history, or implied volatility extrapolated from ImmunomeInc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of ImmunomeInc Fundamentals Over Time. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for ImmunomeInc Stock analysis
When running ImmunomeInc's price analysis, check to measure ImmunomeInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunomeInc is operating at the current time. Most of ImmunomeInc's value examination focuses on studying past and present price action to predict the probability of ImmunomeInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunomeInc's price. Additionally, you may evaluate how the addition of ImmunomeInc to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is ImmunomeInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunomeInc. If investors know ImmunomeInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunomeInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.706 | Return On Assets (0.21) | Return On Equity (1.56) |
The market value of ImmunomeInc is measured differently than its book value, which is the value of ImmunomeInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunomeInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunomeInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunomeInc's market value can be influenced by many factors that don't directly affect ImmunomeInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunomeInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunomeInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunomeInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.